Income statement, balance sheet and cash flow statement for the last 6 fiscal years, taken from the XBRL data Vor Biopharma Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Research and development
31.6
47.5
64.6
94.3
93.3
322
General and administrative
11.7
21.5
28.9
31.7
27.9
50.1
Operating expenses
43.4
69
93.4
126
121
372
Operating income
-43.4
-69
-93.4
-126
-121
-372
Interest income
0.03
0.12
1.32
8.17
4.27
5.87
Other non-operating income
0.03
0.12
1.32
8.17
4.27
-324
Net income
-43.3
-68.9
-92.1
-118
-117
-696
EBITDA
-42.8
-67.6
-90.9
-123
-118
-369
EPS, basic
-4,615.00
-42.04
-46.64
-35.03
-34.03
-70.50
EPS, diluted
-4,615.00
-42.04
-46.64
-35.03
-34.03
-70.50
Shares, basic (weighted)
0.01
1.67
1.98
3.36
3.44
9.87
Shares, diluted (weighted)
0.01
1.67
1.98
3.36
3.44
9.87
Balance sheet
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
48.5
120
57.7
31.4
81.9
396
Short-term investments
0
87.7
173
106
9.98
58.7
Other current assets
0.1
2.09
2.34
0.48
0.38
1.75
Total current assets
49.1
214
237
141
96.5
458
Property, plant and equipment
4.73
6.85
12.6
10.1
6.58
0.53
Lease right-of-use assets
17.1
15.7
44.4
40
35
2.94
Other non-current assets
3.4
3.26
2.93
4.81
2.38
2.38
Total assets
75.9
243
299
198
143
464
Accounts payable
2.36
1.55
1.77
0.82
1.51
5.13
Accrued liabilities
6.26
6.34
7.89
10.9
12.9
19.8
Total current liabilities
10.2
10.2
13.1
15.6
18.6
25.2
Lease liabilities
17.4
16.2
35.6
31.8
27.6
2.72
Total liabilities
27.6
26.3
48.8
47.4
46.2
628
Paid-in capital
2.16
346
474
491
554
989
Retained earnings
-61.2
-130
-222
-340
-457
-1,153
Other comprehensive income
-0.77
-0.08
0.02
0.04
Shareholders' equity
-59.1
216
251
151
96.7
-164
Total equity
-59.1
216
251
151
96.7
-164
Total liabilities and equity
75.9
243
299
198
143
464
Shares outstanding
0.03
1.86
3.3
3.39
6.24
38.7
Cash flow statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-43.3
-68.9
-92.1
-118
-117
-696
Depreciation and amortization
0.61
1.43
2.53
3.49
3.53
2.89
Stock-based compensation
1.34
4.32
10.7
13.4
9.85
18.9
Change in payables
5.82
0.41
1.11
2.85
2.24
10.9
Cash from operations
-36.3
-69.1
-85.1
-100
-99.7
-143
Capital expenditures
-4.16
-3.89
-8.46
-1.07
-0.23
-0.94
Purchases of investments
-87.8
-123
-74.9
-9.91
-53.7
Sales and maturities of investments
37.6
147
107
5
Cash from investing
-4.16
-91.7
-94.1
71
96.9
-48.8
Stock issued
0.26
0.55
4.45
4.58
0.28
70.1
Dividends paid
0
0
0
0
0
0
Cash from financing
82.5
233
117
2.94
53.4
504
Net change in cash
42.1
72.1
-62.1
-26.3
50.6
312
Free cash flow
-40.5
-73
-93.6
-101
-99.9
-144
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to September 30, 2026; growth uses fiscal years. Valuation uses the share price of $19.56 on November 10, 2026.
Profitability
Metric
Value
How it is calculated
Return on assets (ROA)
272.8%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
-270.0%
Book value vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
224.8%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
15.7%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
43.6%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
187.3%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
71.0%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
291.9%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
13.5x
Current assets / current liabilities.
Quick ratio
13.2x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
13.2x
(Cash + short-term investments) / current liabilities.
Free cash flow / net income, when net income is positive.
Per share
Metric
Value
How it is calculated
EPS, diluted
$22.69
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share
-$2.01
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$2.00
Cash from operations / diluted weighted shares.
Book value per share
-$2.23
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/E
0.85x
Market cap / net income. Only when net income is positive.
FCF yield
-10.3%
Free cash flow / market cap.
Earnings yield
117.0%
Net income / market cap (the inverse of P/E).
Was Vor Biopharma Inc. profitable in fiscal 2025?
No. It reported a net loss of $696.0M.
How much free cash flow did Vor Biopharma Inc. generate in fiscal 2025?
Cash from operations of $142.7M minus capital expenditures of $941.0K left free cash flow of -$143.7M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.